A Study To Evaluate The Treatment Pattern Of Moderate-to-Severe Asthma Patients In China

CompletedOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

March 22, 2024

Primary Completion Date

March 13, 2025

Study Completion Date

March 13, 2025

Conditions
Moderate-to-Severe Asthma
Trial Locations (31)

Unknown

Research Site, Baoding

Research Site, Beijing

Research Site, Changsha

Research Site, Chengdu

Research Site, Chongqing

Research Site, Dingzhou

Research Site, Hangzhou

Research Site, Harbin

Research Site, Hefei

Research Site, Hohhot

Research Site, Jinan

Research Site, Kunming

Research Site, Liuzhou

Research Site, Lu'an

Research Site, Luzhou

Research Site, Nanchang

Research Site, Nanchong

Research Site, Qingdao

Research Site, Quanzhou

Research Site, Shanghai

Research Site, Shenzhen

Research Site, Tianjin

Research Site, Tiaobingshan

Research Site, Wenzhou

Research Site, Wuhan

Research Site, Xi'an

Research Site, Xiamen

Research Site, Yongzhou

Research Site, Zhangjiagang

Research Site, Zhengzhou

Research Site, Zigong

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY